

Vaishali Pharma Ltd.



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : sales@vaishalipharma.com
CIN - L52310MH2008PLC181632

24th July, 2021

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Stock Code: VAISHALI

**SUB: OUTCOME UNDER OF THE MEETING OF THE BOARD OF DIRECTORS OF THE COMPANY
HELD TODAY ON 24TH JULY, 2021.**

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the Un-audited Standalone Financial Results along with Limited Review Report for the Quarter Ended 30th June 2021, copy of the same is enclosed herewith.

Further, the Board Meeting commenced at 03:00 pm and concluded at 03:30 pm.

Kindly take the above on records.

Thanking you.

Yours faithfully,
For Vaishali Pharma Limited

Akshay Jharkhandi



Akshay Jharkhandi
Company Secretary & Compliance Officer

Enclosed:-

- Un-Audited Standalone Financial Results for the Quarter Ended 30th June, 2021;
- Limited Review Report issued by Chartered Accountant, M/s. Raman S. Shah & Associates, Chartered Accountants, for the Quarter Ended 30th June, 2021.

Vaishali Pharma Ltd.



Certification Partner Global
ISO 9001:2015 Certified



GOVT. RECOGNIZED
STAR EXPORT HOUSE



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : sales@vaishalipharma.com
CIN - L52310MH2008PLC181632

Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2021

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended
		30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations				
	a) Sales/Income from operations	813.85	1,772.77	345.63	5,230.77
	b) Other operating income	13.14	115.39	11.00	146.62
	Total Revenue from operations	826.99	1,888.16	356.63	5,377.39
2	Other income	56.67	57.33	54.17	180.91
3	Total Income (1+2)	883.66	1,945.49	410.80	5,558.30
4	Expenditure				
	a) Purchase of Stock-in-trade	629.33	1,736.57	277.89	4,585.96
	b) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-trade	(1.10)	35.89	25.87	29.19
	c) Employee benefit expenses	41.93	48.96	45.61	184.77
	d) Finance cost	65.20	106.74	44.41	261.07
	e) Depreciation and amortisation expenses	10.19	11.30	10.26	42.69
	f) Other expenses	29.86	202.70	6.43	314.17
	Total Expenses (a to f)	775.41	2,142.16	410.47	5,417.85
5	Profit before Exceptional Items and Tax	108.25	(196.67)	0.33	140.45
6	Exceptional items debit / (credit)	-	-	-	-
7	Profit before Tax	108.25	(196.67)	0.33	140.45
8	Tax Expenses				
	Current Tax (Net) Debit / (Credit)	27.06	(49.77)	0.10	37.88
	Deferred Tax (Net) Debit / (Credit)	-	(2.06)	-	(2.06)
	Tax for earlier year	-	-	-	-
	Total Tax Expenses	27.06	(51.83)	0.10	35.82
9	Net Profit for the period	81.19	(144.84)	0.23	104.63
10	Other Comprehensive Income				
	a) Items that will not be reclassified to profit and loss (Net of Tax)				
	- Remeasurements of the defined benefit plans : (Losses)/ Gains	-	(0.91)	-	(0.91)
11	Total comprehensive income for the period	81.19	(145.75)	0.23	103.72
12	Paid up Equity Share Capital (Face Value of Rs. 10/-)	1,054.62	1,054.62	1,054.62	1,054.62
13	Earning Per Share (For continuing operations based on Weighted Average) -In INR (Not Annualised)				
	Basic	0.77	(1.37)	0.01	0.99
	Diluted	0.77	(1.37)	0.01	0.99

For and on behalf of the Board

Place : Mumbai
Date : 24/07/2021



FOR VAISHALI PHARMA LTD.

Atul D. V.
DIRECTOR



Vaishali Pharma Ltd.



Certification Partner Global
ISO 9001 : 2015 Certified



GOVT. RECOGNIZED
STAR EXPORT HOUSE



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : sales@vaishalipharma.com
CIN - L52310MH2008PLC181632

1. The above financial results for the quarter ended 30th June, 2021 were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 24th July, 2021.
2. The above Unaudited Financial results is subject to Limited Review Report as furnished by the Statutory Auditors and approved by the Board of Directors of the Company as received under regulation 33 of SEBI (LODR) Regulation 2015.
3. Figures of previous reporting periods have been regrouped / reclassified wherever necessary to correspond with the figures of the current reporting period.
4. The Company has one segment of activity viz., Sale of pharmaceutical products.

Place : Mumbai
Date : 24th July 2021



By the order of the Board
For Vaishali Pharma Limited

Director



**RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS**

CA Raman S. Shah, B.Com ,F.C.A.
CA Santosh A. Sankhe, B.Com ,F.C.A.
CA Bharat C. Bhandari, B.Com ,F.C.A.



LIMITED REVIEW REPORT

To,
The Board of Directors
VAISHALI PHARMA LTD.

1. We have reviewed the accompanying statement of unaudited standalone financial results of VAISHALI PHARMA LTD for the period ended 30th June, 2021 & year to date results for the period 1st April, 2021 to 30th June, 2021 attached herewith.
2. The preparation of the statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (IND-AS) and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circulars issued from time to time including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Raman S. Shah & Associates
Chartered Accountants**



CA Santosh A. Sankhe
Partner

Membership No:- 100976

FRN No:- 119891W

Place : Mumbai

Date : 24th July, 2021

UDIN 21100976AAAAEQ2604

Head Office :- Sam Plaza, 'A' Wing, IInd Floor, H.K. Irani Road, Dahanu Road (W) 401602
Branch Office:- 1) A-104, Ist Floor, Inder Darshan Building, Jamli Gali, Borivali (W), Mumbai (W), 400092
2) 118-121, Ist Floor, "Harmony Plaza", Tarapur Road, Boisar, 401501